Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer.

Trial Profile

Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Capecitabine (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 27 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top